Novo Nordisk A/S (NVO)

FDA Win Boosts Struggling Pharmaceutical Stock

Pharmaceutical powerhouse Novo Nordisk (NYSE:NVO) is charging 3.1% higher to trade at $54.10, after its weight-loss drug Wegovy landed Food and Drug Administration (FDA) approval to be used in the treatment of liver disease in the U.S. Today's pop comes just weeks after the company slashed its 2025 profit outlook and appointed a new CEO, resulting in a 21.8% bear gap on July 29, its worst drop on record.

Novo Nordisk's Weight-Loss Drug Wegovy Approved to Treat Liver Disease

U.S.-listed shares of Novo Nordisk (NVO) gained 4% in premarket trading after the Food and Drug Administration (FDA) approved the pharmaceutical firm's popular weight-loss drug, Wegovy, to treat a serious liver disease.

Novo Nordisk to offer Ozempic for $499 per month

Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients to access authentic Ozempic for $499 per month.

Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

Novo Nordisk said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price through multiple platforms. Patients can pay $499 in cash per month for three dose sizes of Ozempic through the drug's official website, Novo Nordisk's patient assistance program, the company's recently launched direct-to-consumer online pharmacy and drug savings company GoodRx, among other platforms.

Class Action Filed Against Novo Nordisk A/S (NVO) - September 30, 2025 Deadline to Join - Contact The Gross Law Firm

NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO). Shareholders who purchased shares of NVO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Novo Nordisk A/S (“Novo” or the “Company”) (NYSE: NVO) between May 7 , 202 5 and July 28 , 202 5, inclusive. Should You Join This Class Action Lawsuit?

Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.

Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and Ozempic for diabetes.

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

Novo Nordisk shares pop 5% after Wegovy receives U.S. approval for liver disease

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with moderate to advanced liver fibrosis.

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or "the Company") (NYSE: NVO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 7, 2025 and July 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 30, 2025.

Novo Nordisk shares are rising. The FDA approves another use for Wegovy.

Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy to treat a form of liver disease.

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks.

Novo Nordisk's Wegovy gets accelerated US FDA approval for liver disease MASH

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-associated steatohepatitis.

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

DEADLINE ALERT for FLYW, LMT, SOC, NVO: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes

The pricing of weight-loss drugs like Lilly's Zepbound and Novo's Wegovy is a pressure point for investors.

Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo" or the …

Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?

Maziar Mike Doustdar takes office as NVO's new CEO, bringing a proven global growth record to tackle rising obesity market competition.

September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO

NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Novo investors who were adversely affected by alleged securities fraud between May 7, 2025 and July 28, 2025.

DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

It's Time To Be All-In On Novo Nordisk

Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempic and Wegovy, are driving robust growth, but competition from Eli Lilly and compounded versions present near-term headwinds. Strong fundamentals include industry-leading margins, high ROE, consistent share buybacks, and a fast-growing dividend yield, supporting long-term shareholder value.

A Cure For Novo Nordisk

NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47.50 is a strong technical support; I expect stabilization and a gradual recovery from this level.

Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa., Aug. 13, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).

Novo Nordisk Rises 6% So Far in August: How to Play the Stock

NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.

Novo Nordisk: The Falling Knife That Keeps Giving

Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in obesity, cardiovascular, and rare diseases, including promising drugs like oral semaglutide and Mim8. Shareholder returns are supported by strong free cash flow, double-digit profit growth, and disciplined capital expenditures for future expansion.

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options

Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the “Class Period”).

Here's Why Novo Nordisk (NVO) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.